Just three years ago, Circassia was riding high, raising £200 million ($285 million) from its initial public offering (IPO), making it the most successful European biotech stock launch ever.

Analyst James Orsborne of Stifel Nicolaus assigned a Buy rating on Circassia Pharmaceuticals (NIOX – Research Report), with a price target of ...

Circassia plans to the use the proceeds to fund the purchase of two companies - Sweden's Aerocrine and UK-based Prosonix - that will allow it to expand into asthma and other respiratory diseases ...

Circassia Pharmaceuticals ( (GB:NIOX)) has shared an update. Niox Group PLC, a UK-based company, has reported a change in major holdings due to Danske Bank A/S crossing a voting rights threshold.

The ban was introduced in Dagestan, Ingushetia, Kabardino-Balkaria, Karachai-Circassia, North Ossetia, Chechnya, Donetsk and Lugansk People’s Republics, Zaporozhye and Kherson Regions MOSCOW ...